Business Context and Reporting Period
Company: BioCardia, Inc.
Filing Type: Form 8-K (Current Report)
Date: May 28, 2026
Context: The filing reports a significant regulatory milestone regarding the CardiAMP® cell therapy for ischemic heart failure of reduced ejection fraction (HFrEF) in Japan.
Key Financial Metrics
This Form 8-K is a regulatory disclosure and does not contain financial statements. The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Regulatory Developments
- PMDA Consultation Record: Japan's Pharmaceutical and Medical Device Agency (PMDA) issued a record supporting the submission for regulatory approval of CardiAMP® for ischemic HFrEF.
- Clinical Trial Basis: The support is based on three completed clinical trials showing credible positive outcomes.
- Target Population: The therapy targets patients with elevated NTproBNP biomarkers on stable guideline-directed medical therapy (GDMT). Approximately 20,000 of 300,000 patients in Japan are estimated to be initially eligible.
- Regulatory Requirements: PMDA requested demonstration that enrolled patients were on GDMT and ineligible for revascularization, plus additional details on all-cause deaths, heart transplants, or left ventricular assist device implantations.
Clinical Outcomes and Management Commentary
Dr. Raval, representing the CardiAMP CMI Investigators, presented results indicating the therapy was well tolerated with no treatment-emergent major adverse cardiac events. Key clinical outcomes include:
- Exercise Tolerance: Increased by an average of 179 seconds, persisting through the two-year follow-up.
- Angina Reduction: Episodes reduced by an average of 82% by six months post-treatment.
- Patient Profile: All patients were on GDMT and had exhausted available percutaneous or surgical options prior to treatment.
Investor Verification Checklist
- Verify the specific details of the PMDA Consultation Record regarding the remaining questions for regulatory approval.
- Confirm the timeline for the formal regulatory submission to the PMDA following this consultation.
- Review the attached press release (Exhibit 99.1) for full details on the clinical trial data and safety profile.
- Monitor for updates on the specific data requests regarding all-cause mortality and device implantations.